Ones To Watch News
Refine Search
Pharmaceutical
Israel-headquartered clinical-stage diabetes specialist Oramed Pharmaceuticals saw its shares rise as much as 3.3% to $7.82 in early trading, after it revealed signing an exclusive commercial distribution agreement for South Korea with Medicox Co. 14 November 2022
Pharmaceutical
Switzerland’s Relief Therapeutics was up 6.5% this morning after it announced definitive settlement agreements with NRx Pharmaceuticals to resolve their pending litigation. 14 November 2022
Biotechnology
Harbour BioMed saw its shares close up 12% at HK$1.30 today, on the news that its subsidiary Nano Biosciences has entered into a license and collaboration agreement with US biotech Moderna, a pioneer of messenger RNA (mRNA) therapeutics and vaccines. 11 November 2022
Biosimilars
The European Commission has granted a marketing authorization for Ximluci (ranibizumab), a biosimilar candidate referencing Lucentis, developed by Germany’s STADA Arzneimittel and Sweden’s Xbrane Biopharma. 11 November 2022
Pharmaceutical
A strategic licensing deal has been agreed between Barcelona, Spain-based rare disease company Minoryx Therapeutics and German central nervous system (CNS) specialist Neuraxpharm. 10 November 2022
Biotechnology
Shares of Sino-American biotech BeiGene rose as much as 3.8% to 133.97 renminbi when trading started this morning, as the company released third-quarter 2022 financial results that beat consensus forecasts. 10 November 2022
Pharmaceutical
Artificial intelligence (AI)-driven drug discovery company Insilico Medicine has announced a multi-year, multi-target strategic research collaboration with French pharma major Sanofi. 9 November 2022
Biotechnology
VectorY Therapeutics, a Dutch biotech developing vectorized antibody approaches for neurodegenerative diseases, has named Sander van Deventer, co-founder and formerly chief technology officer, as chief executive. 8 November 2022
Pharmaceutical
Ocuphire Pharma’s leapt nearly 27% to $2.65 in pre-market activity this morning, in reaction to its conclusion of an exclusive license agreement with FamyGen Life Sciences (Famy) for the development and commercialization of Nyxol (phentolamine mesylate) across three indications in USA, Europe, Japan, India, China and other global markets. 8 November 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Biotechnology
US biotech Mirum Pharmaceuticals saw its shares rise 3% to $23.69 yesterday, when it presented new data from Livmarli (maralixibat) oral solution studies at The Liver Meeting of the American Association for the Study of Liver Diseases. 8 November 2022
Biotechnology
Shares of Germany-based BioNTech were down 6.8% at $147.48 in pre-market New York trading as it reported third-quarter 2022 financial results, showing that sales and profits were almost half those of the comparable 2021 quarter figures. 7 November 2022
Biotechnology
Shares in Sensorion, a French biotech that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, were trading 17% higher on Monday afternoon. 7 November 2022
Biotechnology
France’s GenSight Biologics saw its shares close up 8.7% at 3.71 euros on Friday, after it announced it has entered into a 35 million-euro ($34.6 million) credit facility agreement with the European Investment Bank (EIB), supported by the European Fund for Strategic Investment (EFSI). 7 November 2022
Pharmaceutical
US drug developer Ionis Pharmaceuticals saw its shares close down 8.5% at $40.98 on Friday, after it revealed that its licensing partner, Germany’s Bayer, had pulled out of a deal for the development of fesomersen. 5 November 2022
Pharmaceutical
Japanese drugmaker Kissei Pharmaceutical has entered into a license agreement with Synmosa Biopharma for the development and commercialization rights in Taiwan for the GnRH antagonist linzagolix that was discovered by Kissei. 4 November 2022
Pharmaceutical
Shares of Swiss biopharma Kinarus Therapeutics Holding ( were down 13% by midday after it confirmed plans to focus on clinical trials of its lead candidate KIN001 in ophthalmic and pulmonary fibrosis indications, and to refocus its capital resources and financing efforts to drive these programs. 4 November 2022
Biotechnology
Shares of US gene and cell therapy company Abeona Therapeutics hit a high of $4.80 yesterday but closed 13% lower at $3.87, after it announced positive top-line data from its pivotal Phase III VIITAL study assessing the safety and efficacy of EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), as well as a $35 million financing. 4 November 2022
Biotechnology
Germany’s Affimed saw its shares leap more than 17% to $1.98 today, after it revealed a collaboration with privately held US biotech Artiva Biotherapeutics. 3 November 2022
Biotechnology
Times are tough for cell medicine specialist Rubius Therapeutics, with the firm announcing plans to slash its workforce by 84%, part of a drastic effort to avoid bankruptcy. 3 November 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze